RxDoctor Payments Data

Aaron Tolan, MD

Internal Medicine · Clemson, SCNPI 1881909596

Payments from drug & device makers

$7,818in general payments, 2019–2025

Across 477 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$830
  • Novo Nordisk$732
  • Pfizer$690
  • Teva Pharmaceuticals USA, Inc.$517
  • GSK$336
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$7,818100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,818 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$117,142
Medicare patients
156
Services billed
4,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide41$56,280
JardianceEmpagliflozin39$45,657
OzempicSemaglutide23$38,080
EliquisApixaban33$34,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$28,608
Synjardy XrEmpagliflozin/Metformin Hcl18$19,921
VraylarCariprazine Hcl14$19,242
UbrelvyUbrogepant13$14,446
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$12,400
Tetrabenazine13$10,676
MyrbetriqMirabegron11$7,706
GlyxambiEmpagliflozin/Linagliptin25$6,681
Atorvastatin Calcium278$4,340
Duloxetine Hcl65$4,139
Allopurinol29$3,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$68$72,25982 claims
Lilly USA, LLCMounjaro$830$56,28041 claims
Novo NordiskOzempic$732$38,08023 claims
PfizerEliquis, Paxlovid$690$35,64747 claims
AbbVieVraylar, Ubrelvy$1,714$33,68827 claims
GSKTrelegy Ellipta$336$28,60831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Clemson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →